Long COVID Atlas
Text Theme
Note

Education, not medical advice. Do not start, stop, or change any medication or supplement without your own clinician, who knows your history and other medicines.

Treatment · Immunology

H1/H2 antihistamines

Cheap, familiar allergy drugs are among the most-tried long COVID treatments, on the theory that overactive mast cells are flooding the body with histamine. Combined H1 and H2 blockade helps a subset, though the evidence is still observational.

Short version: pairing an H1 and an H2 antihistamine dampens histamine and helps some people with mast-cell-type long COVID symptoms. Low-risk, widely tried, but not yet proven in randomized trials.

Blocking histamine on two fronts

Combining an H1 blocker (such as fexofenadine) with an H2 blocker (such as famotidine) dampens histamine signaling, the rationale being mast cell activation in long COVID.1

One cell, many symptoms triggers:foods, heat, stress, infection mast cell degranulates mediators flood out:histamine, tryptase,prostaglandins flushing, hives, gut upset,palpitations, brain fog
Mast cells are immune cells that store packets of inflammatory chemicals. Ordinary triggers, foods, heat, stress, infection, can make them dump those chemicals (histamine and others) into the body at once. Because mast cells sit near vessels, gut, skin, and nerves, one overreacting cell type can produce flushing, hives, gut upset, palpitations, and fog together.

What the evidence says

Reports describe symptom relief in a subset of patients using combined H1-H2 blockade, and these inexpensive, familiar drugs are already widely trialed clinically. The evidence is observational, not yet from large randomized trials.1, 2

subset benefit reported RCT evidence lacking

Where it fits

Because the drugs are low-risk and over-the-counter in many places, a supervised trial is reasonable for people with histamine-type symptoms (flushing, hives, gut upset, palpitations). Benefit, when it comes, is usually partial.

What we don't know

Honest about the edges of the evidence. These are open questions, not settled answers.

  • Who responds and why.
  • Whether benefit beats placebo in a randomized trial.
  • Best H1/H2 combinations and doses.

References

Every reference is free to read in full.

  1. Mast cell activation symptoms prevalent in long COVID (Weinstock et al., IJID 2021).
  2. Mast cell activation syndrome and long COVID (review of treatment rationale).

Associated topics

SymptomChronic fatiguea treatment tried